Speaker Name: Prof. Tina Vilsboll, Clinical Professor and Head of Clinic Steno Diabetes Centre, Copenhagen, Denmark.

Explore the session to:

• Understand the growing global burden of diabesity and its contribution to T2D, HTN, and CVD.
• Gain insight into the interrelationship between CV, renal, and metabolic disease, including overlap with CKD and MASH.
• Review updated nomenclature from NAFLD to MASLD/MASH and its clinical implications.
• Interpret the role of noninvasive fibrosis assessment, including FIB-4, ELF, VCTE, and MRE.
• Explore weight-loss targets and emerging pharmacologic therapies for MASLD/MASH and obesity.